Pediatric brain tumours are abnormal growths that develop in the brain or other parts of the central nervous system during childhood or adolescence. They are the most common solid tumours in children and include many biologically distinct conditions.
Some pediatric brain tumours are slow-growing and remain localised, while others grow rapidly or spread through the cerebrospinal fluid to other areas of the brain or spinal cord. Even a non-cancerous tumour can cause serious problems because the skull provides limited space and the tumour may affect areas responsible for movement, vision, speech, hormones, learning, or other essential functions.
At Apollo Cancer Centres, pediatric brain tumour care is planned by a multidisciplinary team that may include pediatric neuro-oncologists, pediatric neurosurgeons, radiation oncologists, neuroradiologists, neuropathologists, endocrinologists, genetic specialists, rehabilitation professionals, psychologists, and supportive-care teams. Treatment is individualised according to the tumour's type, molecular features, location, extent, the child's age, and the need to protect neurological and developmental function.
Risk Factors for Pediatric Brain Tumours
Pediatric Brain Tumours Signs and Symptoms
How Pediatric Brain Tumours Are Diagnosed
Diagnosis begins with a detailed review of symptoms, development, school performance, medical history, previous radiation exposure, and family history. The doctor assesses vision, hearing, muscle strength, sensation, reflexes, coordination, balance, eye movements, speech, and other neurological functions.
Imaging identifies the tumour's location, size, relationship to essential brain structures, and whether it has spread through the central nervous system. Surgery or biopsy usually provides tissue for an integrated pathological and molecular diagnosis.
MRI
Contrast-enhanced MRI is the principal imaging test for a suspected pediatric brain tumour. It provides detailed images of the brain, tumour, surrounding swelling, blood vessels, ventricles, cranial nerves, and nearby structures. MRI can help determine whether the tumour is well-circumscribed or infiltrative and whether it causes hydrocephalus, bleeding, cyst formation, or pressure on the brainstem. The imaging pattern may suggest a particular tumour type but does not usually replace tissue diagnosis. Thin-slice MRI is used for surgical and radiation planning. Young children may require sedation or anesthesia to remain still during the scan.
Spinal MRI
MRI of the entire spine may be performed when the tumour type can spread through the cerebrospinal fluid. This includes medulloblastoma, other embryonal tumours, ependymoma, germ-cell tumours, atypical teratoid/rhabdoid tumour, and selected high-grade gliomas. Spinal MRI can show tumour deposits along the spinal cord, meninges, or nerve roots. It is also required when the child has back pain, limb weakness, altered sensation, or bladder and bowel symptoms. When possible, staging spinal MRI is performed before surgery because postoperative changes can complicate interpretation.
CT Scan
CT may be used when urgent imaging is required or MRI cannot be performed immediately. It can quickly identify hydrocephalus, bleeding, calcification, skull involvement, or substantial pressure within the brain. CT may provide useful information for tumours that commonly contain calcification or involve bone. However, it provides less soft-tissue detail than MRI. Because CT uses ionising radiation, exposure is limited through pediatric imaging protocols. MRI is generally preferred for detailed diagnosis and follow-up.
Functional MRI and Tractography
Functional MRI may be performed when a tumour lies near areas responsible for movement, speech, or another essential function. It maps brain activity while the child performs selected tasks. Diffusion-tensor imaging and tractography show important white-matter pathways around the tumour. These findings help the neurosurgical team select an approach that reduces the risk of neurological injury. The tests are used selectively and depend on the child's age, ability to cooperate, tumour location, and planned surgery.
Advanced MRI
Perfusion imaging assesses blood flow within and around the tumour. Diffusion imaging provides information about tumour cellularity, while magnetic resonance spectroscopy measures selected chemical characteristics. These techniques may help narrow the diagnosis, identify the most appropriate biopsy area, and distinguish viable tumour from treatment-related change. They may also contribute to response assessment. Advanced MRI findings are interpreted alongside conventional imaging, pathology, molecular testing, and the clinical picture. They cannot independently establish the tumour type.
PET Imaging
PET imaging may be used selectively to evaluate tumour metabolism or clarify an uncertain MRI finding. Different tracers may be used according to the tumour type and clinical question. PET can sometimes help identify active tumour, guide biopsy, assess treatment response, or distinguish recurrence from radiation-related tissue injury. Its role is not the same for every pediatric brain tumour, and it does not replace high-quality contrast-enhanced MRI.
Stereotactic Biopsy
A stereotactic biopsy may be performed when complete removal is unsafe or when the diagnosis is required before selecting treatment. Image guidance directs a biopsy needle through a small opening in the skull to obtain tumour tissue. It may be appropriate for deep-seated, infiltrative, midline, or brainstem tumours. The biopsy trajectory is planned to avoid important blood vessels and functional brain pathways. Multiple samples may be collected to support histopathology, immunohistochemistry, molecular testing, and DNA methylation profiling. Some tumours can vary within different areas, making adequate tissue sampling important.
Open Biopsy
An open biopsy may be performed when a larger tissue sample is required or the tumour's location allows direct surgical access. It may be selected when stereotactic sampling is unlikely to provide sufficient tissue. The surgeon removes part of the tumour without attempting complete resection. This may be appropriate when the tumour infiltrates essential brain structures or when extensive removal would cause unacceptable neurological harm. The pathological and molecular diagnosis then guides chemotherapy, radiation, targeted therapy, or further surgery.
Surgical Resection
For many tumours, diagnosis and treatment begin with maximal safe surgical removal. The operation provides tissue and reduces tumour volume or pressure on the brain. A postoperative MRI is usually performed within a defined period to assess the extent of removal. This information contributes to staging, risk classification, and further treatment planning. The amount safely removed depends on tumour location, infiltration, vascularity, and proximity to essential neurological structures. Complete removal is not always the safest or most appropriate objective.
Cerebrospinal Fluid Analysis
Cerebrospinal fluid may be examined when the tumour type can spread through the fluid surrounding the brain and spinal cord. Cytology looks for tumour cells, while tumour markers or molecular tests may be added for selected diagnoses. Lumbar puncture is generally performed only after brain imaging has been reviewed and raised intracranial pressure has been addressed. It may be delayed until after surgery when immediate sampling would be unsafe. The timing varies by tumour type. Postoperative sampling may be scheduled after sufficient recovery to reduce the possibility of misleading findings caused by surgery.
Laboratory
The tissue collected during biopsy or surgery may undergo:
Histopathology: Evaluates the tumour's microscopic appearance, cellular features, growth pattern, and areas of necrosis or abnormal cell division.
Tumour grading: Assigns a World Health Organization grade where applicable, although molecular type may be as important as grade.
Immunohistochemistry: Uses protein markers to identify the tumour lineage and distinguish between glioma, ependymoma, embryonal tumour, germ-cell tumour, craniopharyngioma, and other conditions.
Molecular classification: Identifies gene alterations, fusions, amplifications, deletions, or pathway changes that define the tumour type.
Histone testing: H3 K27 and H3 G34 alterations help classify selected pediatric diffuse high-grade gliomas.
MAPK-pathway testing: BRAF alterations, NF1-associated changes, and other MAPK-pathway abnormalities may occur in pediatric low-grade gliomas.
Ependymoma testing: ZFTA or YAP1 fusions and posterior-fossa molecular groups can help classify ependymal tumours.
Medulloblastoma testing: Molecular assessment distinguishes WNT-activated, SHH-activated, and non-WNT/non-SHH tumours and contributes to risk assessment.
Rhabdoid-tumour testing: Loss of SMARCB1/INI1 or SMARCA4 expression and corresponding molecular alterations support the diagnosis of atypical teratoid/rhabdoid tumour.
Germ-cell tumour markers: Alpha-fetoprotein and beta-human chorionic gonadotropin may be measured in blood and cerebrospinal fluid when an intracranial germ-cell tumour is suspected.
DNA methylation profiling: This may resolve a difficult diagnosis by comparing the tumour's molecular pattern with recognised central nervous system tumour classes.
Blood tests may include a complete blood count, kidney and liver function, electrolytes, coagulation studies, and hormone levels. Endocrine testing is particularly important for tumours near the pituitary gland, hypothalamus, or optic pathways.
There is no single stage I-to-IV system that applies to all pediatric brain tumours. Classification and treatment planning depend on the tumour's integrated diagnosis, location, molecular features, World Health Organization grade, extent of removal, and whether it has spread through the central nervous system.
Tumour Type
Pediatric brain tumours include several broad groups:
Low-grade gliomas: Generally slow-growing tumours that include pilocytic astrocytoma and several molecularly defined gliomas.
High-grade gliomas: Faster-growing tumours that include diffuse midline glioma and other pediatric-type diffuse high-grade gliomas.
Embryonal tumours: Include medulloblastoma and other rapidly growing tumours that may spread through cerebrospinal fluid.
Ependymomas: Develop from cells lining the ventricles or central canal of the spinal cord and include several molecular groups.
Germ-cell tumours: Usually arise near the pineal or suprasellar regions and may be germinomatous or non-germinomatous.
Craniopharyngiomas: Usually develop near the pituitary gland and hypothalamus and can substantially affect vision and hormone function.
Choroid-plexus tumours: Develop in tissues that produce cerebrospinal fluid and may range from benign papilloma to carcinoma.
Atypical teratoid/rhabdoid tumours: Aggressive tumours occurring mainly in infants and young children.
How Pediatric Brain Tumours Are Treated
Maximal Safe Resection
Maximal safe resection removes as much tumour as possible without causing unacceptable neurological injury. It is the principal treatment for many localised pediatric brain tumours. Complete removal may be possible for well-circumscribed tumours located away from essential brain structures. Infiltrative tumours or those involving the brainstem, hypothalamus, optic pathways, or major blood vessels may require partial resection or biopsy. The expected benefit of additional removal is balanced against possible effects on movement, speech, vision, memory, hormones, personality, swallowing, and independence.
Image-Guided Surgery
Neuronavigation uses preoperative MRI or CT to guide the surgeon to the tumour. Intraoperative ultrasound or MRI may help identify residual disease and account for shifts in brain position during surgery. Functional mapping and neurophysiological monitoring may be used when the tumour is close to areas involved in movement, language, vision, hearing, or other essential functions. Fluorescence-guided techniques may be considered for selected tumours. Their usefulness depends on tumour biology, age, location, and available evidence.
Awake and Functional Surgery
Awake surgery may be considered for selected older children and adolescents with tumours near language or other functional areas. The child performs tasks during part of the procedure so the surgical team can map and protect essential brain regions. Careful psychological preparation and cooperation are required. Awake surgery is not appropriate for every child or tumour. Younger children may undergo surgery under general anesthesia with neurophysiological monitoring and other functional-preservation techniques.
CSF Diversion
A tumour may block cerebrospinal fluid flow and cause hydrocephalus. Treatment may involve removing the obstructing tumour, performing an endoscopic third ventriculostomy, or inserting a temporary or permanent drainage device. An external ventricular drain may be used for short-term pressure control. A ventriculoperitoneal shunt may be required when hydrocephalus persists. The appropriate procedure depends on tumour location, cause of obstruction, age, infection risk, and expected duration of the problem.
Second-Look Surgery
A second operation may be considered when residual tumour remains after initial surgery and further removal becomes safer or clinically important. This may occur after the child has recovered, after tumour shrinkage with chemotherapy, or when specialist imaging clarifies the residual disease. The potential improvement in tumour control is weighed against the risk of neurological impairment. Second-look surgery is not necessary for every residual tumour. The decision is made after multidisciplinary review of pathology, molecular findings, imaging, and response to treatment.
Chemotherapy
Chemotherapy is used for several pediatric brain tumour types. It may be given after surgery, before radiation, to delay radiation in very young children, or to treat residual, metastatic, recurrent, or progressive disease. The medicines used depend on the tumour. Regimens may include carboplatin, cisplatin, vincristine, cyclophosphamide, lomustine, etoposide, temozolomide, methotrexate, or other agents in protocol-defined combinations. Treatment requires monitoring for low blood counts, infection, nausea, kidney injury, hearing loss, nerve effects, fertility effects, and other toxicities. The potential benefits are balanced against short- and long-term effects on the developing child.
High-Dose Chemotherapy
High-dose chemotherapy followed by autologous stem-cell rescue may be used for selected aggressive tumours, particularly in infants or young children when reducing or delaying radiation exposure is important. The child's blood-forming stem cells are collected and stored before intensive treatment. They are returned after chemotherapy to restore bone-marrow function. This approach is not appropriate for every tumour. It requires specialist transplant expertise and intensive monitoring for infection, organ toxicity, nutritional problems, and other complications.
Targeted Therapy
Molecular testing may identify a pathway or alteration that can be treated with a targeted medicine. BRAF and MEK inhibitors may be used for selected pediatric low-grade gliomas with relevant MAPK-pathway alterations. Other targeted treatments may be considered for tumours with NTRK, ALK, FGFR, mTOR-pathway, or other actionable changes. Suitability depends on tumour type, age, previous treatment, available evidence, and medicine access. Targeted therapy can control some tumours for prolonged periods but may not permanently eliminate them. Treatment requires monitoring for skin, heart, eye, liver, growth, and other potential effects.
Immunotherapy and Clinical Trials
Immunotherapy has a limited established role in most pediatric brain tumours because the immune environment and molecular features differ from those of many adult cancers. Selected children with particular biomarkers, inherited mismatch-repair deficiency, or recurrent disease may benefit from an immune-checkpoint inhibitor or another immune-based approach. Clinical trials may evaluate vaccines, cellular therapies, antibody-based treatments, oncolytic viruses, and novel targeted medicines. Participation depends on the tumour type, molecular findings, previous treatment, and trial eligibility.
Focal Radiation Therapy
Focal radiation treats the tumour or surgical bed while limiting exposure to the rest of the brain. It may be used for ependymoma, high-grade glioma, selected low-grade glioma, germ-cell tumours, craniopharyngioma, and other tumour types. The treatment area and dose depend on pathology, molecular diagnosis, age, extent of removal, residual tumour, and nearby structures. Image guidance and conformal planning are used to protect the brainstem, optic pathways, cochleae, pituitary gland, hippocampi, and healthy developing brain where possible.
Craniospinal Irradiation
Craniospinal irradiation treats the entire brain and spinal cerebrospinal fluid pathways. It is used for selected tumours with a recognised risk of spread through cerebrospinal fluid, such as medulloblastoma and certain other embryonal or germ-cell tumours. A focused boost is then delivered to the primary tumour site or visible metastatic deposits. The dose depends on tumour type, risk group, age, response to therapy, and presence of disseminated disease. Treatment planning aims to limit exposure to the heart, lungs, thyroid, bowel, bone marrow, reproductive organs, and growing tissues.
Stereotactic Radiation Therapy
Stereotactic radiosurgery or fractionated stereotactic radiation may be considered for selected small, well-defined, residual, or recurrent tumours. It delivers a highly focused radiation dose while limiting exposure to surrounding brain. Fractionated treatment may be preferred for lesions close to the optic pathways, brainstem, or other sensitive structures. The technique is not appropriate for diffuse or widespread disease. Suitability depends on tumour type, size, location, previous radiation, and the child's age.
Proton Therapy
Proton therapy may be considered when reducing radiation exposure to healthy developing tissues provides a meaningful advantage. Protons can reduce the exit dose beyond the target compared with some photon-radiation plans. This may help limit exposure to the normal brain, cochleae, pituitary gland, heart, lungs, bowel, bone marrow, and other organs. It can be particularly relevant for craniospinal irradiation or tumours near critical structures. For appropriate patients, Apollo Proton Cancer Centre can compare proton and advanced photon-radiation plans. Proton therapy does not remove all risks of radiation and is recommended when it provides a clinically meaningful dosimetric or treatment advantage.
Re-Irradiation
Radiation may occasionally be considered when a tumour recurs after previous radiation. Modern focal techniques can sometimes treat a limited area while reducing additional exposure to previously treated tissues. The decision depends on the original radiation dose, time since treatment, tumour type, location, volume, symptoms, and available alternatives. Re-irradiation requires specialist review because the risk of radiation injury increases when normal brain tissue has already received treatment.
The outlook varies widely because pediatric brain tumours include many different diseases. Some localised low-grade tumours can be controlled with surgery alone, while diffuse, high-grade, metastatic, or recurrent tumours are more difficult to treat.
Survival statistics cannot predict exactly what will happen to an individual child. Tumours with similar appearances can behave differently because of their molecular features and location.
Long-term follow-up is important even after successful treatment. Survivorship care monitors neurological function, growth, hormones, vision, hearing, learning, fertility, cardiovascular health, emotional well-being, and the risk of recurrence or treatment-related second tumours.
Why Choose ACC for Pediatric Brain Tumour Treatment